Published in Vaccine Weekly, April 5th, 2006
Study 1: Therapeutic cancer vaccines amplify tumor-specific regulatory T cells.
According to researchers in the United States, "The fate of tumor-specific CD4+ T cells is central to the outcome of the host immune response to cancer. We show that tumor antigen recognition by a subset of CD4+ T cells led to their differentiation into cells capable of suppressing naive and Th1 effector cells."
"Such tumor-induced regulatory T cells (TMTregs) arose both from precommitted 'natural' regulatory T cells and CD4+CD25-GITRlow precursors," said Gang Zhou and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly